Best treatments for castration-resistant prostatic neoplasms
3 products may treat castration-resistant prostatic neoplasms, spanning FDA drug classes such as cytochrome p450 17a1 inhibitor. The current highest-rated option is abiraterone acetate. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.
Quick answer: Of the 3 drugs we list for castration-resistant prostatic neoplasms, all are available as lower-cost generics, spanning classes such as cytochrome p450 17a1 inhibitor. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for castration-resistant prostatic neoplasms — so confirm the right choice with your prescriber.
| # | Drug | Rating | Type | Form | Class | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Tablet | Cytochrome P450 17A1 Inhibitor | Generic | $26 | View → | |
| 2 | Not yet rated | Prescription | Tablet | Cytochrome P450 17A1 Inhibitor | Generic | $26 | View → | |
| 3 | Not yet rated | Prescription | Tablet | Cytochrome P450 17A1 Inhibitor | Generic | $26 | View → |
Narrow by drug class
Explore the class hubs: cytochrome p450 17a1 inhibitor
Full ranking · 3 treatments
abiraterone acetate
PrescriptionFDA-sourced
Abiraterone Acetate is a cytochrome p450 17a1 inhibitor used to treat Castration-Resistant Prostatic Neoplasms.
Pharmacy pays
From ~$24.97/30· 2 formsyonsa
PrescriptionFDA-sourced
Yonsa (Abiraterone Acetate) is a cytochrome p450 17a1 inhibitor used to treat Castration-Resistant Prostatic Neoplasms.
Pharmacy pays
From ~$24.97/30· 2 formszytiga
PrescriptionFDA-sourced
Zytiga (Abiraterone Acetate) is a cytochrome p450 17a1 inhibitor used to treat Castration-Resistant Prostatic Neoplasms.
Pharmacy pays
From ~$24.97/30· 2 formsFrequently asked
- What treats castration-resistant prostatic neoplasms?
- Our catalog lists 3 products that may treat castration-resistant prostatic neoplasms, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is abiraterone acetate.
- What is the best-rated treatment for castration-resistant prostatic neoplasms?
- By our independent recall-safety rating — not an efficacy measure — abiraterone acetate ranks highest among the products we list for castration-resistant prostatic neoplasms. Always consult a professional.
- How are these treatments ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
- What types of drugs treat castration-resistant prostatic neoplasms?
- Treatments for castration-resistant prostatic neoplasms span FDA drug classes including cytochrome p450 17a1 inhibitor. Compare every option side by side, ranked by independent rating, above.
Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.